News and Views.
- Published in:
- Diabetes, Obesity & Metabolism, 2012, v. 14, n. 1, p. 97, doi. 10.1111/j.1463-1326.2011.01541.x
- By:
- Publication type:
- Article
Works matching DE "TAKEDA Pharmaceutical Co. Ltd."
Results: 59
1
2
Syrrx acquisition signals maturation of structure-based discovery.
- Published in:
- Nature Biotechnology, 2005, v. 23, n. 4, p. 400, doi. 10.1038/nbt0405-400
- By:
- Publication type:
- Article
3
Approved indication: Hodgkin lymphoma, anaplastic large cell lymphoma.
- Published in:
- 2014
- Publication type:
- Product Review
4
New drugs.
- Published in:
- 2014
- Publication type:
- Product Review
5
Joint drug venture to end after 30 years.
- Published in:
- Nature, 2008, v. 452, n. 7186, p. 399, doi. 10.1038/452399c
- Publication type:
- Article
6
New diabetes pill.
- Published in:
- British Journal of Community Nursing, 2006, v. 11, n. 11, p. 498
- Publication type:
- Article
7
IADC Amicus Brief Program.
- Published in:
- Defense Counsel Journal, 2015, v. 82, n. 4, p. 460, doi. 10.12690/0895-0016-82.4.460
- Publication type:
- Article
8
Syntheses of [<sup>14</sup>C]-labeled 2-(3-chlorophenyloxy)-3-[3-(3-hydroxy) pyridin-4-yl propoxy]pyridine, a phosphodiesterase 4 inhibitor and its metabolites.
- Published in:
- Journal of Labelled Compounds & Radiopharmaceuticals, 2014, v. 57, n. 7, p. 477, doi. 10.1002/jlcr.3211
- By:
- Publication type:
- Article
9
The Impact of Serotype Cross-Protection on Vaccine Trials: DENVax as a Case Study.
- Published in:
- Vaccines, 2020, v. 8, n. 4, p. 674, doi. 10.3390/vaccines8040674
- By:
- Publication type:
- Article
10
New indication.
- Published in:
- Formulary, 2008, v. 43, n. 6, p. 188
- Publication type:
- Article
11
Update: pioglitazone patent term extension.
- Published in:
- Formulary, 2006, v. 41, n. 12, p. 671
- Publication type:
- Article
12
New formulations.
- Published in:
- 2006
- Publication type:
- Product Review
13
A year of novel pharmacologic agents in review.
- Published in:
- Formulary, 2005, v. 40, n. 11, p. 382
- Publication type:
- Article
14
Alliances.
- Published in:
- Applied Clinical Trials, 2005, v. 14, n. 9, p. 70
- Publication type:
- Article
15
Interview with Dr. Nandu Gattu.
- Published in:
- 2016
- By:
- Publication type:
- Interview
16
Takeda and Eli Lilly Announce A Cardiovascular Outcome Study with Pioglitazone.
- Published in:
- Diabetes, Obesity & Metabolism, 2001, v. 3, n. 2, p. 123
- Publication type:
- Article
17
The Bill and Melinda Gates Foundation.
- Published in:
- Journal of Global Health, 2013, v. 3, n. 1, p. 11, doi. 10.7189/jogh.03.010202
- Publication type:
- Article
18
Drug Developments and STD News.
- Published in:
- AIDS Patient Care & STDs, 2005, v. 19, n. 5, p. 350, doi. 10.1089/apc.2005.19.350
- Publication type:
- Article
19
Business digest.
- Published in:
- Chemistry & Industry, 2015, v. 79, n. 10, p. 19, doi. 10.1002/cind.7910_5.x
- Publication type:
- Article
20
Movers & Shakers.
- Published in:
- Chemistry & Industry, 2012, v. 76, n. 9, p. 46, doi. 10.1002/cind.7609_13.x
- Publication type:
- Article
21
Business digest.
- Published in:
- Chemistry & Industry, 2009, n. 15, p. 13
- By:
- Publication type:
- Article
22
Mixed performance around the world.
- Published in:
- Chemistry & Industry, 2008, n. 16, p. 7
- By:
- Publication type:
- Article
23
Business Digest.
- Published in:
- Chemistry & Industry, 2008, n. 11, p. 15
- By:
- Publication type:
- Article
24
FDA insists on cardiac warning for Avandia.
- Published in:
- Chemistry & Industry, 2007, n. 16, p. 10
- By:
- Publication type:
- Article
25
ORAL PRESENTATION Developmental situation of hypnotics in Japan.
- Published in:
- Sleep & Biological Rhythms, 2004, v. 2, p. S3, doi. 10.1111/j.1479-8425.2004.00084.x
- By:
- Publication type:
- Article
26
Dengue Vaccine by Takeda Show Overall Effectivity in the Study, Comes with a Limitation.
- Published in:
- Indian Practitioner, 2019, v. 72, n. 11, p. 48
- Publication type:
- Article
27
Takeda's integrin inhibitor scores inflammatory bowel disease approvals.
- Published in:
- Nature Reviews Drug Discovery, 2014, v. 13, n. 7, p. 485, doi. 10.1038/nrd4388
- Publication type:
- Article
28
Lead GPR40 agonist bites the dust.
- Published in:
- Nature Reviews Drug Discovery, 2014, v. 13, n. 2, p. 91, doi. 10.1038/nrd4246
- Publication type:
- Article
29
Tachi Yamada.
- Published in:
- Nature Reviews Drug Discovery, 2013, v. 12, n. 9, p. 658, doi. 10.1038/nrd4110
- Publication type:
- Article
30
Drug Discovery Process: A Case Study on Takeda.
- Published in:
- 2016
- By:
- Publication type:
- Case Study
31
Industry News.
- Published in:
- BioEssays, 2010, v. 32, n. 6, p. A3
- By:
- Publication type:
- Article
32
Takeda's Largest Study Brings Dengue Vaccine Step Closer.
- Published in:
- Clinical Infectious Diseases, 2017, v. 65, n. 1, p. ii
- By:
- Publication type:
- Article
33
News Blast.
- Published in:
- Bio-IT World, 2005, v. 4, n. 3, p. 12
- Publication type:
- Article
34
Takeda and Shire agree £46bn takeover.
- Published in:
- TCE: The Chemical Engineer, 2018, n. 924, p. 17
- Publication type:
- Article
35
Takeda mulls bid for Shire.
- Published in:
- TCE: The Chemical Engineer, 2018, n. 923, p. 19
- Publication type:
- Article
36
New gout treatment approved.
- Published in:
- American Journal of Health-System Pharmacy, 2009, v. 66, n. 7, p. 606, doi. 10.2146/news090028
- By:
- Publication type:
- Article
37
Recent data show Takeda's promising angiotensin II receptor blocker azilsartan is also effective in combination.
- Published in:
- Expert Review of Cardiovascular Therapy, 2011, v. 9, n. 7, p. 811
- Publication type:
- Article
38
Brazilian drug companies hope to benefit from foreign investment.
- Published in:
- Nature Medicine, 2011, v. 17, n. 10, p. 1171, doi. 10.1038/nm1011-1171a
- By:
- Publication type:
- Article
39
Avandia outcome may signal change in epidemiologists' sway.
- Published in:
- Nature Medicine, 2010, v. 16, n. 6, p. 614, doi. 10.1038/nm0610-614a
- By:
- Publication type:
- Article
40
Zzz…Dreaming of sounder sleep.
- Published in:
- Chemistry & Industry, 2006, n. 3, p. 12
- Publication type:
- Article
41
News feature: 2008 in reflection.
- Published in:
- 2009
- By:
- Publication type:
- journal article
42
News in Brief.
- Published in:
- Nature Reviews Drug Discovery, 2008, v. 7, n. 5, p. 378, doi. 10.1038/nrd2585
- Publication type:
- Article
43
News in Brief.
- Published in:
- Nature Reviews Drug Discovery, 2008, v. 7, n. 3, p. 192, doi. 10.1038/nrd2547
- Publication type:
- Article
44
Patentwatch: You say lactic acid, I say lactide.
- Published in:
- Nature Reviews Drug Discovery, 2005, v. 4, n. 11, p. 876, doi. 10.1038/nrd1890
- By:
- Publication type:
- Article
45
Recent data show Takeda's promising angiotensin II receptor blocker azilsartan is also effective in combination.
- Published in:
- Expert Review of Clinical Pharmacology, 2011, v. 4, n. 4, p. 415
- Publication type:
- Article
46
Takeda told to pay US$6bn over cancer claims.
- Published in:
- TCE: The Chemical Engineer, 2014, n. 875, p. 6
- Publication type:
- Article
47
Takeda to buy Nycomed for €9.6b.
- Published in:
- TCE: The Chemical Engineer, 2011, n. 841, p. 9
- Publication type:
- Article
48
Takeda buys Millennium Pharma.
- Published in:
- TCE: The Chemical Engineer, 2008, n. 803, p. 8
- Publication type:
- Article
49
The Antidiabetics Market: Tendencies and Research Directions.
- Published in:
- Applied Medical Informatics, 2010, v. 26, n. 1/2, p. 42
- By:
- Publication type:
- Article
50
TAKEDA AGREES TO $62 BILLION TAKEOVER OF SHIRE.
- Published in:
- Applied Clinical Trials, 2018, v. 27, n. 6, p. 13
- Publication type:
- Article